Literature DB >> 31574432

Performance evaluation of a Compton SPECT imager for determining the position and distribution of 225Ac in targeted alpha therapy: A Monte Carlo simulation based phantom study.

Taewoong Lee1, Minho Kim1, Wonho Lee2, Byoungsoo Kim1, Ilhan Lim1, Kanghyon Song1, Jongguk Kim3.   

Abstract

In this study, the performance of a Compton Single Photon Emission Computed Tomography (SPECT) imager when in vivo monitoring the position and distribution of 225Ac radionuclide in targeted alpha therapy (TAT) was evaluated. When 225Ac radionuclide, which emits various γ-rays (218 and 440 keV), is used in TAT, both the photoelectric and Compton scattering events can be used for image reconstruction. Moreover, all information pertaining to the various γ-rays of the 225Ac radionuclide can be individually or simultaneously utilized in the reconstructed image. Three types of simulation phantoms and a quantitative evaluation method were used to compare the performance of the Compton SPECT imager to that of conventional SPECT imaging, which uses only photoelectric events, and the results demonstrated that the Compton SPECT imager exhibited a higher performance as the effective count for the image reconstruction was higher. To verify the accuracy of the position and distribution of the 225Ac radionuclide that had been inserted into the phantom, reconstructed images of the various γ-rays were combined with cross-sectional images of the human phantom and all combined images were found to match the predetermined simulation conditions. In conclusion, the simulation results demonstrated the feasibility of the in vivo monitoring of the position and distribution of 225Ac radionuclide using the γ-rays in TAT.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (225)Ac radionuclide; Compton SPECT imaging; Targeted alpha therapy (TAT)

Year:  2019        PMID: 31574432     DOI: 10.1016/j.apradiso.2019.108893

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  1 in total

Review 1.  KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future.

Authors:  Byung Hyun Byun; Myoung Hyoun Kim; Yeon-Hee Han; Hwan-Jeong Jeong
Journal:  Nucl Med Mol Imaging       Date:  2021-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.